Yang Yang, Xing Yiqiao, Liang Chaoqun, Hu Liya, Xu Fei, Mei Qi
Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue 1095, Wuhan, 430030, China.
Tumour Biol. 2016 May;37(5):6709-18. doi: 10.1007/s13277-015-4444-5. Epub 2015 Dec 9.
We aimed to explore molecular mechanism and drug candidates of vascular toxicities associated with melphalan after treating human retinal endothelial cells (RECs). GSE34381 microarray data was firstly downloaded and used to identify the differentially expressed genes (DEGs) in human REC treated with melphalan vs. untreated cells by limma package in R language. The transcription network was constructed based on TRANSFAC database and the top five transcription factors (TFs) were select with a measure of regulatory impact factor, followed by the construction of function modules. Gene ontology enrichment analyses were performed to explore the enriched functions. Connectivity Map analysis was conducted to predict the potential drugs overcoming the melphalan's actions on REC. Totally, 75 DEGs were identified, including 70 up-regulated and five down-regulated genes. Transcription network with 1311 nodes and 1875 edges was constructed and the top five TFs were CREM, MYC, FLI1, NF-κB1, and JUN. Functional modules indicated that NF-κB1 and MYC were the important nodes. The upregulated genes as well as the genes involved in the modules mainly participated in biological process of immune response, cell proliferation, and cell motion. Five small molecules were predicted to be potential drug candidates, including doxorubicin, fipexide, daunorubicin, tiabendazole, and GW-8510. Based on these results, we speculate that NF-κB1 and MYC might involve in the molecular mechanism of vascular toxicity induced by melphalan through regulating their target genes. Five small molecules might be drug candidates to overcome the melphalan-induced vascular toxicity via targeting to MYC and JUN.
我们旨在探讨美法仑处理人视网膜内皮细胞(RECs)后血管毒性的分子机制和候选药物。首先下载GSE34381芯片数据,并用R语言中的limma软件包识别经美法仑处理的人REC与未处理细胞中差异表达基因(DEGs)。基于TRANSFAC数据库构建转录网络,通过调节影响因子选择前五个转录因子(TFs),随后构建功能模块。进行基因本体富集分析以探索富集功能。进行连通性图谱分析以预测克服美法仑对REC作用的潜在药物。总共鉴定出75个DEGs,包括70个上调基因和5个下调基因。构建了具有1311个节点和1875条边的转录网络,前五个TFs为CREM、MYC、FLI1、NF-κB1和JUN。功能模块表明NF-κB1和MYC是重要节点。上调基因以及模块中涉及的基因主要参与免疫反应、细胞增殖和细胞运动的生物学过程。预测了五种小分子为潜在候选药物,包括阿霉素、非哌西特、柔红霉素、噻苯达唑和GW-8510。基于这些结果,我们推测NF-κB1和MYC可能通过调节其靶基因参与美法仑诱导的血管毒性分子机制。五种小分子可能是通过靶向MYC和JUN克服美法仑诱导的血管毒性的候选药物。